NXS Stock Overview Engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Next Science Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Next Science Historical stock prices Current Share Price AU$0.12 52 Week High AU$0.50 52 Week Low AU$0.11 Beta 1.55 1 Month Change -17.86% 3 Month Change -41.03% 1 Year Change -62.90% 3 Year Change -90.50% 5 Year Change -93.80% Change since IPO -91.25%
Recent News & Updates
Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024 Oct 16
New minor risk - Share price stability Sep 12
Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024 Jul 26
Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024 Jul 10
New minor risk - Share price stability Apr 24
Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024 Apr 23 See more updates
Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024 Oct 16
New minor risk - Share price stability Sep 12
Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024 Jul 26
Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024 Jul 10
New minor risk - Share price stability Apr 24
Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024 Apr 23
Next Science Limited, Annual General Meeting, May 03, 2024 Mar 04
Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022) Feb 29
Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 16 Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Nov 01
Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director Oct 24
New minor risk - Shareholder dilution Sep 07
First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022) Sep 03
New minor risk - Financial data availability Aug 30
Next Science Limited Announces Board Changes Aug 23 Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer
New minor risk - Share price stability Jun 30
Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products Jun 29 Next Science Limited Announces Executive Changes
Founder & CTO recently sold AU$1.5m worth of stock Mar 13
Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021) Feb 28 Next Science Limited, Annual General Meeting, May 26, 2023
Forecast breakeven date pushed back to 2024 Jan 31 Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited Dec 13
Insufficient new directors Nov 16
Next Science Limited Announces the Launch of Topical Collagen Products Oct 19
Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE Aug 26
Forecast breakeven date pushed back to 2024 Aug 26
Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022 Aug 11
Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer May 28
Insufficient new directors Apr 27
MD, CEO & Executive Director recently sold AU$123k worth of stock Apr 02
Next Science Limited, Annual General Meeting, May 27, 2022 Mar 30
Forecast to breakeven in 2024 Mar 04
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 25
Insufficient new directors Dec 06
Founder & CTO recently sold AU$8.6m worth of stock Sep 08
Forecast to breakeven in 2023 Sep 06
First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020) Sep 03
Forecast to breakeven in 2023 Sep 01
Next Science Limited Agrees to Open Negotiations with Zimmer, Inc Jun 25
Next Science Limited Provides Revenue Guidance for the First Half of 2021 Jun 12
Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia May 28
Independent Non-Executive Chairman George Savvides has left the company May 08
Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA Apr 29
Independent Non-Executive Director recently sold AU$564k worth of stock Apr 28
Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA Apr 27
Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019) Apr 05
Next Science Limited, Annual General Meeting, May 05, 2021 Mar 04
New 90-day high: AU$1.37 Feb 25
Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019) Feb 23
Revenue beats expectations Feb 23
Next Science Limited to Report Fiscal Year 2020 Results on Feb 22, 2021 Feb 12
Next Science Limited Receives CE Mark Approval for BlastX Dec 21
New 90-day high: AU$1.36 Dec 03
Non-Executive Director recently bought AU$149k worth of stock Nov 28
Next Science Limited Announces Non-Renewal of Distribution Agreement With 3M Nov 23
MD, CEO & Director recently bought AU$217k worth of stock Nov 01
New 90-day low: AU$1.16 Oct 27
Non-Executive Director recently bought AU$192k worth of stock Oct 06
Non-Executive Director recently bought AU$263k worth of stock Sep 29
New 90-day low: AU$1.20 Sep 24
Next Science Limited(ASX:NXS) dropped from S&P Global BMI Index Sep 21
Earnings released Aug 26
Next Science Limited to Report First Half, 2020 Results on Aug 26, 2020 Aug 12 Shareholder Returns NXS AU Medical Equipment AU Market 7D -8.0% -1.1% -2.7% 1Y -62.9% 0.4% 6.5%
See full shareholder returns
Return vs Market: NXS underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility Is NXS's price volatile compared to industry and market? NXS volatility NXS Average Weekly Movement 13.6% Medical Equipment Industry Average Movement 8.8% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: NXS's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: NXS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Show more Next Science Limited Fundamentals Summary How do Next Science's earnings and revenue compare to its market cap? NXS fundamental statistics Market cap AU$35.06m Earnings (TTM ) -AU$21.59m Revenue (TTM ) AU$37.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NXS income statement (TTM ) Revenue US$23.31m Cost of Revenue US$4.93m Gross Profit US$18.37m Other Expenses US$31.87m Earnings -US$13.50m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.046 Gross Margin 78.83% Net Profit Margin -57.93% Debt/Equity Ratio 0%
How did NXS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 12:06 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Next Science Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Elyse Shapiro Bell Potter Martyn Jacobs Canaccord Genuity Dr Benson Wilsons Advisory and Stockbroking Ltd.
Show 1 more analysts 
